Showing results (81-90 of 156) with videos related to
Sort By:
Pageof 16
Oncology|June 6, 2015
Outcomes of Systemic Therapy for Patients with Metastatic AngiosarcomaSandra P D'Angelo, Rodrigo R Munhoz, Deborah Kuk, et al.Clinical Lung Cancer|July 22, 2014
Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutationJamie E Chaft, Anya Litvak, Maria E Arcila, et al.British Journal of Cancer|October 10, 2013
High-risk features in radiation-associated breast angiosarcomasS P D'Angelo, C R Antonescu, D Kuk, et al.Cell Reports. Medicine|March 7, 2025
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignanciesJuanita S Lopez, Mohammed Milhem, Marcus O Butler, et al.The American Journal of Surgical Pathology|July 17, 2014
Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutationKyuichi Kadota, Yi-Chen Yeh, Sandra P D'Angelo, et al.NPJ Precision Oncology|March 25, 2025
Immunologic correlates in a CIC::DUX4 fusion-positive sarcoma responsive to dual immune checkpoint blockadeOlayode O Babatunde, Sara Coca Membribes, Cristina Anthonescu, et al.Investigational New Drugs|November 12, 2017
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanomaSandra P D'Angelo, Omid A Hamid, Ahmad Tarhini, et al.Sarcoma|June 18, 2016
Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine LeiomyosarcomaA N Shoushtari, J Landa, D Kuk, et al.JAMA Oncology|April 29, 2016
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical TrialMark A Dickson, Gary K Schwartz, Mary Louise Keohan, et al.Journal for Immunotherapy of Cancer|July 24, 2021
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II studySandra P D'Angelo, Celeste Lebbé, Laurent Mortier, et al.Pageof 16